Aspergillosis Treatment Market Size & Share 2024 - 2032

Aspergillosis Treatment Market Size

Aspergillosis treatment market size was valued at around USD 3.8 billion in 2023 and is estimated to grow at 4.3% CAGR from 2024 to 2032. Aspergillosis treatment, where aspergillosis is a group of fungal infections caused by aspergillus species, commonly found indoors and outdoors. It ranges from mild to severe and predominantly affects individuals with weakened immune systems or existing lung conditions.

The rising incidence of aspergillosis is a significant driver for the market. For instance, according to the Centers for Disease Control and Prevention (CDC’s) report indicates that approximately 2.5% of adults diagnosed with asthma also suffer from allergic bronchopulmonary aspergillosis (ABPA), totaling around 4.8 million individuals globally. Among these ABPA cases, an estimated 400,000 people additionally contend with chronic pulmonary aspergillosis (CPA), in 2024.

Therefore, this underscores the growing importance of addressing fungal infections, particularly in individuals with underlying respiratory conditions, which necessitates heightened awareness, research, and treatment options. Furthermore, growing awareness of fungal infections and development of new antifungal agents, are driving factors for the market growth.

Aspergillosis Treatment Market Trends

The development of new antifungal agents brings several advantages to the treatment of aspergillosis. Firstly, it can expand the available treatment options, providing physicians with more choices to tailor therapy based on factors such as the patient's condition, the severity of the infection, and any underlying health issues. Additionally, new antifungal agents may offer improved efficacy, enabling more effective eradication of the aspergillus fungus and better outcomes for patients.
 

• The introduction of new antifungal drugs, which is estimated to reach USD 21.2 billion by 2032, broadens the array of treatment choices available to healthcare providers. This diversity allows clinicians to select the most appropriate medication based on factors such as the patient's medical history, the severity of the infection, potential drug interactions, and the presence of any underlying conditions.
   
• New antifungal agents often undergo rigorous testing to ensure their efficacy against aspergillus species. They may exhibit superior potency or have unique mechanisms of action compared to older medications. Improved efficacy means better control of the fungal infection, potentially leading to faster resolution of symptoms and reduced risk of complications.
   
• Additionally, aspergillus species, such as other fungi, have the potential to develop resistance to antifungal medications over time. The development of new drugs with different mechanisms of action can help combat this resistance. By targeting the fungus in novel ways, new antifungal agents may circumvent resistance mechanisms that have developed against older medications.
   

Aspergillosis Treatment Market Analysis

Based on type, the market is divided into acute aspergillosis and chronic aspergillosis. The acute aspergillosis segment of the market is forecasted to reach USD 4.3 billion by 2032.
 

• Improved diagnostic techniques, such as molecular assays and imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI), facilitate early detection of acute aspergillosis. Early diagnosis enables prompt initiation of treatment, is crucial for improving patient outcomes.
   
• Antifungal agents specifically targeting aspergillus such as voriconazole and isavuconazole are the mainstay of treatment for acute aspergillosis. These drugs have demonstrated efficacy in both empirical and targeted therapy. Advancements in antifungal therapy include the development of novel agents with improved potency, broader spectrum of activity, and better safety profiles.
   
• Further, combination therapy involving two or more antifungal agents may be considered for severe or refractory cases of acute aspergillosis. This approach aims to enhance antifungal efficacy, prevent the emergence of resistance, and improve patient outcomes, thus driving the market growth.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on drug class, the aspergillosis treatment market is bifurcated into antifungal drugs, corticosteroids, and other drug classes. Further, antifungal drugs is segmented into azoles, echinocandins, polyenes, allylamines, and other antifungal drugs. The corticosteroids segment is divided into prednisolone, prednisone, methylprednisolone, and other corticosteroids. The antifungal drugs segment accounted for USD 2.4 billion in 2023.
 

• Antifungal drugs such as azoles, echinocandins and polyenes have demonstrated efficacy in treating various forms of aspergillosis. They target different components of the fungal cell wall or membrane, leading to fungal cell death or inhibition of growth.
   
• Many antifungal drugs have activity against a broad spectrum of fungal pathogens, including different species of aspergillus. This broad-spectrum activity is advantageous in treating aspergillosis, can be caused by various aspergillus species with differing susceptibilities to antifungal agents.
   
• Further, antifungal drugs are available in various formulations, including oral tablets, intravenous (IV) formulations, and inhaled formulations. This versatility allows for tailored treatment approaches based on the severity of the infection, patient preferences, and clinical circumstances. Thus, propelling the growth of the market.
   

Based on drug form, the aspergillosis treatment market is divided into oral, injections, ointments, and powders. Further oral segment is segmented into tablets and capsules. The oral segment of the market is forecasted to reach USD 2.2 billion by 2032.
 

• Oral administration allows patients to take medication at home, reducing the need for hospitalization or frequent visits to healthcare facilities. This convenience can improve patient adherence to treatment regimens, especially for long-term therapy required in chronic forms of aspergillosis.
   
• Oral antifungal therapy facilitates outpatient management of aspergillosis, enabling patients to maintain their daily activities and quality of life while undergoing treatment. Outpatient care also reduces healthcare costs associated with hospital stays and medical appointments.
   
• Oral formulations of antifungal drugs offer flexibility in dosing and administration schedules, allowing healthcare providers to tailor treatment regimens to individual patient needs. This flexibility is particularly beneficial for patients with comorbidities or those taking multiple medications.
   

Based on distribution channel, the aspergillosis treatment market is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is forecasted to reach USD 3 billion by 2032.
 

• Hospital pharmacies are well-equipped with a comprehensive inventory of antifungal medications, including those that may not be readily available in retail pharmacies. This ensures that patients have timely access to the most appropriate and effective treatments for aspergillosis.
   
• Hospital pharmacists possess specialized knowledge and expertise in managing complex fungal infections such as aspergillosis. They collaborate closely with infectious disease specialists, pulmonologists, and other healthcare providers to optimize antifungal therapy, adjust dosages, and manage potential drug interactions and side effects.
   
• Hospital pharmacies have the capability to compound medications tailored to individual patient needs. This is particularly useful for patients who require specific formulations or dosages that are not commercially available, ensuring personalized and precise treatment for aspergillosis.
   

The growth of the aspergillosis treatment market in the U.S., projected to reach USD 2 billion by 2032.
 

• The U.S. has a highly developed healthcare system with state-of-the-art hospitals and medical facilities equipped with the latest technologies. This infrastructure supports advanced diagnostic and treatment capabilities for aspergillosis, ensuring high-quality patient care.
   
• The U.S. is at the forefront of pharmaceutical research and development. Patients in the U.S. have access to the latest antifungal medications and treatment protocols, including new drug formulations and novel therapies that are often first introduced in the U.S. market.
   

The aspergillosis treatment market in UK is expected to experience significant and promising growth from 2024 to 2032.
 

• The UK's National Health Service (NHS) provides universal healthcare coverage, ensuring that all residents have access to necessary medical treatments, including those for Aspergillosis. This universal access helps in early diagnosis and consistent treatment across the population.
   

Japan aspergillosis treatment market is anticipated to witness lucrative growth between 2024 – 2032.
 

• Japan is known for its innovation in medical technology. Advanced diagnostic tools, such as high-resolution imaging and molecular diagnostics, are widely available, enabling early and accurate diagnosis of aspergillosis, which is crucial for effective treatment.
   
• Japan has a strong pharmaceutical industry that collaborates closely with academic institutions and healthcare providers to develop new antifungal agents. This collaboration ensures that patients have access to the latest and most effective treatments for aspergillosis.
   

The market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.

• Saudi Arabia is investing in the development of its pharmaceutical sector, aiming to produce more medications locally and improve access to essential drugs. This includes antifungal medications necessary for the treatment of aspergillosis.
   

Aspergillosis Treatment Market Share

The aspergillosis treatment sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.
 

Aspergillosis Treatment Market Companies

Some of the eminent market participants operating in the aspergillosis treatment industry include:

• Abbott Laboratories
• Astellas Pharma Inc.
• Astra Zeneca PLC
• Basilea Pharmaceutica Ltd.
• Bayer AG
• Endo International plc
• F2G
• GSK plc
• Johnson & Johnson
• Merck & Co., Inc.
• Mayne Pharma Group Limited
• Novartis AG
• PULMATRiX, Inc.
• Takeda Pharmaceutical Company Ltd.
• Viatris Inc.
   

Aspergillosis Treatment Industry News:

• In March 2024, Astellas Pharma US, Inc. announced that the U.S. Food and Drug Administration (FDA) granted orphan drug and pediatric exclusivity to CRESEMBA (isavuconazonium sulfate) for treating invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients. This designation benefits the company by providing market exclusivity, enhancing its reputation for addressing unmet medical needs, increasing revenue through expanded use.
   
• In October 2023, Basilea Pharmaceutica Ltd acquired Gravitas Therapeutics Inc., a clinical-stage antifungal compound with a novel mechanism of action targeting invasive mold infections caused by Aspergillus species. This acquisition benefits Basilea by expanding its pipeline with a unique antifungal therapy, enhancing its competitive edge, addressing a significant unmet medical need, aligning with its strategic growth objectives, and providing opportunities for further development and commercialization.
   

The aspergillosis treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Acute aspergillosis
• Chronic aspergillosis

Market, By Drug Class

• Antifungal drugs
  • Azoles
  • Echinocandins
  • Polyenes
  • Allylamines
  • Other antifungal drugs
• Corticosteroids
  • Prednisolone
  • Prednisone
  • Methylprednisolone
  • Other corticosteroids
• Other drug classes

Market, By Drug Form

• Oral
  • Tablets
  • Capsules
• Injections
• Ointments
• Powders

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa